FDA approves Novo Nordisk’s Wegovy to reduce cardiovascular risks

The U.S. Food and Drug Administration approved Novo Nordisk’s weight-loss drug Wegovy on Friday to reduce the risk of stroke and heart attack in overweight or obese adults without diabetes. 

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM